Scholarlink

Objective <p>Clinical studies have confirmed the impact of PD-1/PD-L1 inhibitors like Nivolumab, Pembrolizumab, Avelumab, and Atezolizumab on ovarian cancer. This meta-analysis aims to examine the effectiveness of anti-PD-1/PD-L1 therapies specifically in platinum-resistant ovarian cancer.</p> Methods <p>A systematic search was conducted in PubMed, Embase, and Cochrane Library until June 2024. We used a combination of keywords including ovarian cancer, and PD-1, PD-L1 inhibitor. The combined objective response rate (ORR) and disease control rate (DCR) were statistically analyzed using R version 4.3.3. Additional subgroup analyses were conducted to determine the factors influencing the risk of bias.</p> Results <p>Ten trials involving 571 ovarian cancer (OC) patients were included after a thorough full-text evaluation. A random-effects model was selected, yielding a combined ORR of 12% (95%CI: 7% to 17%), with significant heterogeneity (I2 = 62%, <i>p</i> &lt; 0.01). The combined DCR was 53% (95%CI 44% to 62%) with moderate heterogeneity (I2 = 40%, <i>p</i> = 0.14). Four studies involving single PD-1/PD-L1 inhibitors had usable ORR data., showing a combined ORR of 6% (95%CI: 3% to 9%). Three studies investigating the combination of PD-1/PD-L1 inhibitors with pegylated liposomal doxorubicin (PLD) reported an ORR of 15% (95%CI: 10% to 19%). Two studies on PD-1/PD-L1 inhibitors combined with antiangiogenic therapy showed a combined ORR of 16% (95%CI: 4% to 27%).</p> Conclusion <p>PD-1/PD-L1 inhibitors alone or in combination have limited efficacy for platinum-resistant ovarian cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Efficacy of PD-1/PD-L1 Inhibitors in the Treatment of Platinum-Resistant Ovarian Cancer: A Single-Arm Meta-analysis

  • 期刊论文

  • 发表日期：

    2025年4月16日

查看全文
  • Shally Chandra,
  • Jeannette Tandiono,
  • Sabrina Agatha Jean Aswan,
  • Michael Geraldi Lokanata,
  • Alexy Oktoman Djohansjah

摘要

Objective

Clinical studies have confirmed the impact of PD-1/PD-L1 inhibitors like Nivolumab, Pembrolizumab, Avelumab, and Atezolizumab on ovarian cancer. This meta-analysis aims to examine the effectiveness of anti-PD-1/PD-L1 therapies specifically in platinum-resistant ovarian cancer.

Methods

A systematic search was conducted in PubMed, Embase, and Cochrane Library until June 2024. We used a combination of keywords including ovarian cancer, and PD-1, PD-L1 inhibitor. The combined objective response rate (ORR) and disease control rate (DCR) were statistically analyzed using R version 4.3.3. Additional subgroup analyses were conducted to determine the factors influencing the risk of bias.

Results

Ten trials involving 571 ovarian cancer (OC) patients were included after a thorough full-text evaluation. A random-effects model was selected, yielding a combined ORR of 12% (95%CI: 7% to 17%), with significant heterogeneity (I2 = 62%, p < 0.01). The combined DCR was 53% (95%CI 44% to 62%) with moderate heterogeneity (I2 = 40%, p = 0.14). Four studies involving single PD-1/PD-L1 inhibitors had usable ORR data., showing a combined ORR of 6% (95%CI: 3% to 9%). Three studies investigating the combination of PD-1/PD-L1 inhibitors with pegylated liposomal doxorubicin (PLD) reported an ORR of 15% (95%CI: 10% to 19%). Two studies on PD-1/PD-L1 inhibitors combined with antiangiogenic therapy showed a combined ORR of 16% (95%CI: 4% to 27%).

Conclusion

PD-1/PD-L1 inhibitors alone or in combination have limited efficacy for platinum-resistant ovarian cancer.